This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameMitolactol
Accession NumberDB12916
TypeSmall Molecule
GroupsInvestigational
Description

Mitolactol has been used in trials studying the treatment of Brain and Central Nervous System Tumors.

Structure
Thumb
SynonymsNot Available
External IDs NCI-C04795 / NSC-104800
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIILJ2P1SIK8Y
CAS number10318-26-0
WeightAverage: 307.966
Monoisotopic: 305.910235
Chemical FormulaC6H12Br2O4
InChI KeyVFKZTMPDYBFSTM-GUCUJZIJSA-N
InChI
InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4+,5+,6-
IUPAC Name
(2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol
SMILES
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mitolactol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitolactol.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mitolactol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mitolactol.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Mitolactol.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitolactol.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Mitolactol.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Mitolactol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitolactol.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mitolactol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentBrain and Central Nervous System Tumors1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility39.7 mg/mLALOGPS
logP-0.44ALOGPS
logP-0.65ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.63ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.92 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity50.47 m3·mol-1ChemAxon
Polarizability21.41 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bromohydrins. These are alcohols substituted by a bromine atom at a saturated carbon atom otherwise bearing only hydrogen or hydrocarbyl groups.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassHalohydrins
Sub ClassBromohydrins
Direct ParentBromohydrins
Alternative ParentsSecondary alcohols / Polyols / Organobromides / Hydrocarbon derivatives / Alkyl bromides
SubstituentsSecondary alcohol / Bromohydrin / Polyol / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organobromide / Alkyl halide / Alkyl bromide / Alcohol
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available
Drug created on October 20, 2016 19:15 / Updated on September 01, 2017 12:26